These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 25285015)

  • 1. Clinical significance of UGT1A1 gene polymorphisms on irinotecan-based regimens as the treatment in metastatic colorectal cancer.
    Li M; Wang Z; Guo J; Liu J; Li C; Liu L; Shi H; Liu L; Li H; Xie C; Zhang X; Sun W; Fang S; Bi X
    Onco Targets Ther; 2014; 7():1653-61. PubMed ID: 25285015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The relationship between UGT1A1 gene polymorphism and irinotecan effect on extensive-stage small-cell lung cancer.
    Xiao XG; Xia S; Zou M; Mei Q; Zhou L; Wang SJ; Chen Y
    Onco Targets Ther; 2015; 8():3575-83. PubMed ID: 26664141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. UGT1A1 predicts outcome in colorectal cancer treated with irinotecan and fluorouracil.
    Wang Y; Shen L; Xu N; Wang JW; Jiao SC; Liu ZY; Xu JM
    World J Gastroenterol; 2012 Dec; 18(45):6635-44. PubMed ID: 23236239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation between UGT1A1 gene polymorphism and irinotecan chemotherapy in metastatic colorectal cancer: a study from Guangxi Zhuang.
    Chen S; Hua L; Feng C; Mo Q; Wei M; Shen Y; Lin Z; Li G; Xu J; Guo C; Huang H
    BMC Gastroenterol; 2020 Apr; 20(1):96. PubMed ID: 32264830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Correlation between nUGT1A1 gene polymorphisms and adverse events of irinotecan plus S-1 for patients with recurrent or metastatic esophageal squamous cell carcinoma: a prospective, open-label, randomized controlled trial (ESWN 01)].
    Wang X; Liu Y; Huang JX; Lu P; Ba Y; Wu L; Bai YX; Zhang S; Feng JF; Cheng Y; Li J; Wen L; Yuan XL; Ma CW; Hu CH; Fan QX; Xu BH; Huang J
    Zhonghua Zhong Liu Za Zhi; 2021 Nov; 43(11):1177-1182. PubMed ID: 34794220
    [No Abstract]   [Full Text] [Related]  

  • 6. [Relationship between UGT1A1 gene polymorphisms and irinotecan-induced severe adverse events].
    Wang XF; Ma C; Gong FF; Yi SY; Xing GC; Wang KJ; Yang Q; Cao W
    Zhonghua Zhong Liu Za Zhi; 2018 Aug; 40(8):594-599. PubMed ID: 30139029
    [No Abstract]   [Full Text] [Related]  

  • 7. Distribution of uridine diphosphate glucuronosyltransferase 1A polymorphisms and their role in irinotecan-induced toxicity in patients with cancer.
    Wang Y; Yi C; Wang Y; Li H; Li B; Wang D; Du J; Liu L; Wang X
    Oncol Lett; 2017 Nov; 14(5):5743-5752. PubMed ID: 29113203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. UGT1A1 6/28 polymorphisms could predict irinotecan-induced severe neutropenia not diarrhea in Chinese colorectal cancer patients.
    Gao J; Zhou J; Li Y; Lu M; Jia R; Shen L
    Med Oncol; 2013; 30(3):604. PubMed ID: 23686699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. UGT1A1 Gene Polymorphism Predicts Irinotecan-Induced Severe Neutropenia and Diarrhea in Chinese Cancer Patients.
    Peng H; Duan Z; Pan D; Wen J; Wei X
    Clin Lab; 2017 Sep; 63(9):1339-1346. PubMed ID: 28879724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma.
    Liu CY; Chen PM; Chiou TJ; Liu JH; Lin JK; Lin TC; Chen WS; Jiang JK; Wang HS; Wang WS
    Cancer; 2008 May; 112(9):1932-40. PubMed ID: 18300238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pazopanib-Induced Liver Toxicity in Patients With Metastatic Renal Cell Carcinoma: Effect of UGT1A1 Polymorphism on Pazopanib Dose Reduction, Safety, and Patient Outcomes.
    Henriksen JN; Bøttger P; Hermansen CK; Ladefoged SA; Nissen PH; Hamilton-Dutoit S; Fink TL; Donskov F
    Clin Genitourin Cancer; 2020 Feb; 18(1):62-68.e2. PubMed ID: 31640912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Associations between UGT1A1*6/*28 polymorphisms and irinotecan-induced severe toxicity in Chinese gastric or esophageal cancer patients.
    Gao J; Zhou J; Li Y; Peng Z; Li Y; Wang X; Shen L
    Med Oncol; 2013; 30(3):630. PubMed ID: 23783485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. UGT1A1*6, 1A7*3, and 1A9*22 genotypes predict severe neutropenia in FOLFIRI-treated metastatic colorectal cancer in two prospective studies in Japan.
    Hazama S; Mishima H; Tsunedomi R; Okuyama Y; Kato T; Takahashi K; Nozawa H; Ando H; Kobayashi M; Takemoto H; Nagata N; Kanekiyo S; Inoue Y; Hamamoto Y; Fujita Y; Hinoda Y; Okayama N; Oba K; Sakamoto J; Oka M
    Cancer Sci; 2013 Dec; 104(12):1662-9. PubMed ID: 24033692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between UGT1A1*6/*28 polymorphisms and severe toxicities in Chinese patients with pancreatic or biliary tract cancer treated with irinotecan-containing regimens.
    Yang C; Liu Y; Xi WQ; Zhou CF; Jiang JL; Ma T; Ye ZB; Zhang J; Zhu ZG
    Drug Des Devel Ther; 2015; 9():3677-83. PubMed ID: 26229432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive Value of UGT1A1*28 Polymorphism In Irinotecan-based Chemotherapy.
    Liu XH; Lu J; Duan W; Dai ZM; Wang M; Lin S; Yang PT; Tian T; Liu K; Zhu YY; Zheng Y; Sheng QW; Dai ZJ
    J Cancer; 2017; 8(4):691-703. PubMed ID: 28367249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of UGT1A1(*)28 and (*)6 polymorphisms with irinotecan-induced neutropenia in Thai colorectal cancer patients.
    Atasilp C; Chansriwong P; Sirachainan E; Reungwetwattana T; Chamnanphon M; Puangpetch A; Wongwaisayawan S; Sukasem C
    Drug Metab Pharmacokinet; 2016 Feb; 31(1):90-94. PubMed ID: 26830078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. UGT1A1 Gene Polymorphisms in Patients with Small Cell Lung Cancer Treated with Irinotecan-Platinum Doublet Chemotherapy and Their Association with Gastrointestinal Toxicity and Overall Survival.
    Bandyopadhyay A; Sharma S; Behera D; Singh N
    Oncologist; 2021 Aug; 26(8):701-713. PubMed ID: 33728696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. UGT1A1 gene polymorphism is associated with toxicity and clinical efficacy of irinotecan-based chemotherapy in patients with advanced colorectal cancer.
    Xu C; Tang X; Qu Y; Keyoumu S; Zhou N; Tang Y
    Cancer Chemother Pharmacol; 2016 Jul; 78(1):119-30. PubMed ID: 27220761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Examination of multiple UGT1A and DPYD polymorphisms has limited ability to predict the toxicity and efficacy of metastatic colorectal cancer treated with irinotecan-based chemotherapy: a retrospective analysis.
    Liu D; Li J; Gao J; Li Y; Yang R; Shen L
    BMC Cancer; 2017 Jun; 17(1):437. PubMed ID: 28637434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between
    Bai Y; Wu HW; Ma X; Liu Y; Zhang YH
    Onco Targets Ther; 2017; 10():3071-3081. PubMed ID: 28790841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.